In vitro anti-cancerous activity of Navamani Chenduram (NMC) in ovarian cancer cell line (pa-1) using MTT assay

Ovarian cancer is one of the leading gynaecological issues that contribute to morbidity and mortality, worldwide. Siddha system of medicine has various medicines which can be considered as an alternative form of therapy in cancer management with proising therapeutic efficacy and  minimal contraindications.. The present study is to indicate the anticancer property of Navamani Chenduram, Siddha Metallo mineral formulation through MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay in a dose dependent manner. MTT assay (cytotoxic study) is performed by Serial dilutions of Navamani Chenduram  (10, 50, 100, and 200 μg/ml) and methotrexate 10 μg/ml, as a standard comparison drug on human metastatic ovarian cancer PA-1 cell line. The study was evaluated by assessing the inhibition of the percentage of cell viability and they had minimum viability of cell (40.38 ± 3.122 %,) and high anti-ovarian cancer activities dose-dependently against PA-1.  Our results prove that Navamani Chenduram induces Apoptosis of carcinogenic cells, thus it inhibits the growth of metastatic ovarian cancer cells.